• PDF: Delivered by email usually within 48 UK business hours.

Safinamide
Analysis and Estimates from 2012 to 2020

  • Publication Date:July 2011
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:35

Safinamide Analysis and Estimates from 2012 to 2020

Summary

GlobalData's pharmaceuticals report, ""Safinamide - Analysis and Estimates from 2012 to 2020"" provides Safinamide(sales estimates for US and EU5 . In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the Japan (seven major markets)
  • Analysis and review of Safinamide including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Safinamide including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2012-2020 for Safinamide in the US and EU5

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug's performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Introduction
    • 2.1 Parkinson's Disease
    • 2.2 Symptoms of Parkinson's Disease
    • 2.3 Diagnosis of Parkinson's Disease
    • 2.4 Parkinson's Disease Treatment Strategies
    • 2.5 Parkinson's Disease Market
    • 2.6 Epidemiology
    • 2.7 Parkinson's Disease by Age and Gender
    • 2.8 Etiology
    • 2.9 GlobalData Report Guidance
  • 3 Parkinson's Disease: Market Characterization
    • 3.1 Parkinson's Disease Market
    • 3.2 Parkinson's Disease Market Forecasts and CAGR
    • 3.3 Factors Affecting Parkinson's Disease Market
      • 3.3.1 High Prevalence: Parkinson's Disease is the Second Most Frequent Neurodegenerative Disorder
      • 3.3.2 Increase in Old Age Population
      • 3.3.3 Patent Expiry of Prominent Drugs
  • 4 Stages of Parkinson's Disease and Comparison of Treatments
    • 4.1 The Hoehn and Yahr Scale
    • 4.2 Modified Hoehn and Yahr Scale
    • 4.3 The UPDRS
  • 5 Staging of Parkinson's Disease
    • 5.1 Distribution of Parkinson's Disease Patients by Age Groups
    • 5.2 Distribution of Patients by Stages
  • 6 Safinamide
    • 6.1 Introduction
    • 6.2 Mechanism of Action
    • 6.3 Clinical Studies
      • 6.3.1 SETTLE Study with Safinamide as an Add On to a Dopamine Agonist in Patients with Early Parkinson's Disease
      • 6.3.2 Long Term Efficacy and Safety of Safinamide as an Add On to Levodopa in Patients with Advanced Parkinson's Disease
    • 6.4 Factors Affecting Sales of Safinamide
      • 6.4.1 Add on to DAs
      • 6.4.2 Potential Benefits
      • 6.4.3 Motor and Non Motor Systems
      • 6.4.4 No statistically Significant Improvement in Primary End Point
      • 6.4.5 Patent Expiry of Dopamine Agonists
    • 6.5 Drug Evaluation
      • 6.5.1 Drug Risk Benefit Score
      • 6.5.2 Intensity of Competition
    • 6.6 Sales Forecasts
      • 6.6.1 Target Patient Pool for Safinamide
      • 6.6.2 Dosing
      • 6.6.3 Market Penetration
      • 6.6.4 Annual Cost of Therapy
      • 6.6.5 Sales Projections of Safinamide
  • 7 Parkinson Disease Market: Appendix
    • 7.1 Market Definitions
    • 7.2 List of Abberiviations
    • 7.3 Research Methodology
      • 7.3.1 Coverage
      • 7.3.2 Secondary Research
      • 7.3.3 Forecasting
      • 7.3.4 Number of Patients Approved to take the Drug
      • 7.3.5 Net Penetration of Drug
      • 7.3.6 Net Annual Dosing
      • 7.3.7 Annual Cost of Therapy
      • 7.3.8 Primary Research
      • 7.3.9 Expert Panels
    • 7.4 Drug Sales Estimates Model
    • 7.5 Contact Us
    • 7.6 Disclaimer
    • 7.7 Sources
  • List of Tables
    • Table 1: Clinical Motor and Nonmotor Features of Parkinson's Disease
    • Table 2: Hoehn and Yahr Stages of Parkinson's Disease
    • Table 3: Hoehn and Yahr Stages of Parkinson's Disease
    • Table 4: Four Items, Part 1 of UPDRS
    • Table 5: Thirteen Items, Part 2 of UPDRS
    • Table 6: Fourteen Items, Part 3 of UPDRS
    • Table 7: Fourteen Items, Part 3 of UPDRS
    • Table 8: Distribution of Parkinson's Patients According to Hoehn and Yahr Classification
    • Table 9: UPDRS III Scores in The Intention To Treat Cohort and in Patients Taking One DA Agonist
    • Table 10: Study Results for Safinamide as Add-On to Levodopa In Patients with Advanced Parkinson's Disease
    • Table 11:Drug Risk Benefit Score (DRB)-Safinamide
    • Table 12: Efficacy Comparison of Safinamide with other Competitors
    • Table 13: Annual Cost of Safinamide for Parkinson's Disease, 2011
    • Table 14: Safinamide, Parkinson's Disease, Global, Sales Forecasts ($m), 2012-2020
    • Table 15: Safinamide, Parkinson's Disease, The US, Sales Forecasts ($m), 2012-2020
    • Table 16: Safinamide, Parkinson's Disease, The UK, Sales Forecasts ($m), 2012-2020
    • Table 17: Safinamide, Parkinson's Disease, France, Sales Forecasts ($m), 2012-2020
    • Table 18: Safinamide, Parkinson's Disease, Germany, Sales Forecasts ($m), 2012-2020
    • Table 19: Safinamide, Parkinson's Disease, Italy, Sales Forecasts ($m), 2012-2020
    • Table 20: Safinamide, Parkinson's Disease, Spain, Sales Forecasts ($m), 2012-2020
  • List of Figures
    • Figure 1: Current Pharmacologic Therapies for Parkinson's disease and Their Potential Sites of Action in the CNS
    • Figure 2: The Age-Specific Prevalence Rates of Parkinson's Disease in the Elderly Among Five European Countries, 2003
    • Figure 3: Parkinson's Disease, Global, Market Size Estimates ($bn), 2010-2020
    • Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050
    • Figure 5: Points Distribution of UPDRS
    • Figure 6: Distribution of Parkinson's Disease Patients by Hoehn & Yahr Classification
    • Figure 7: Drug Model Diagram of Safinamide in the US and EU
    • Figure 8: Safinamide, Parkinson's Disease, Global, Sales Forecasts ($m), 2012-2020
    • Figure 9: Safinamide, Parkinson's Disease, The US, Sales Forecasts ($m), 2012-2020
    • Figure 10: Safinamide, Parkinson's Disease, The UK, Sales Forecasts ($m), 2012-2020
    • Figure 11: Safinamide, Parkinson's Disease, France, Sales Forecasts ($m), 2012-2020
    • Figure 12: Safinamide, Parkinson's Disease, Germany, Sales Forecasts ($m), 2012-2020
    • Figure 13: Safinamide, Parkinson's Disease, Italy, Sales Forecasts ($m), 2012-2020
    • Figure 14: Safinamide, Parkinson's Disease, Spain, Sales Forecasts ($m), 2012-2020
    • Figure 15: Safinamide, Parkinson's Disease, Global, Sales Distribution by Country (%), 2020
    • Figure 16: Drug Model Diagram
    • Figure 17: Patients Approved for the Drug
+44 20 8816 8548

Ask a question about Safinamide

Enter the characters you see in the picture below
Captcha